Physician profile
John Strong
NPI 1043248719
$6,162.29
in general payments reported to CMS, 2019-2025
52 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,810 · 2020: $620 · 2021: $647 · 2022: $562 · 2023: $598 · 2024: $889 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,522.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $723.61 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $680.26 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Novo Nordisk INC | $465.27 | 2019-2025 | Wegovy, Saxenda |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $402.78 | 2019-2023 | Trulance, Xifaxan |
| Amgen INC. | $347.04 | 2019-2024 | Repatha, Otezla, Tezspire |
| Merck Sharp & Dohme LLC | $333.12 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $283.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $281.79 | 2019-2025 | |
| Genzyme Corporation | $179.62 | 2024-2025 | |
| Madrigal Pharmaceuticals | $175.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Pharmaceuticals, INC | $153.46 | 2019-2022 | |
| Pfizer INC. | $141.69 | 2019-2025 | |
| Lilly USA, LLC | $141.06 | 2019-2024 | Zepbound, Jardiance |
| Amarin Pharma, INC. | $128.40 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $109.88 | 2023 | Dupixent |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Strong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.